24 years of historical data (2002–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alnylam Pharmaceuticals, Inc. trades at 142.9x earnings, 16% below its 5-year average of 170.7x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 503%. On a free-cash-flow basis, the stock trades at 94.7x P/FCF, 72% below the 5-year average of 342.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $44.1B | $53.6B | $30.0B | $23.9B | $28.9B | $20.1B | $14.9B | $12.6B | $7.3B | $11.5B | $3.2B |
| Enterprise Value | $45.4B | $54.9B | $31.8B | $24.4B | $29.4B | $20.3B | $15.0B | $12.3B | $6.9B | $10.9B | $3.2B |
| P/E Ratio → | 142.88 | 170.67 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 11.87 | 14.42 | 13.36 | 13.08 | 27.88 | 23.79 | 30.32 | 57.26 | 97.91 | 127.96 | 67.96 |
| P/B Ratio | 56.82 | 67.86 | 447.73 | — | — | 34.15 | 14.71 | 8.75 | 5.63 | 6.51 | 3.48 |
| P/FCF | 94.70 | 115.08 | — | 569.99 | — | — | — | — | — | — | — |
| P/OCF | 84.09 | 102.19 | — | 229.54 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Alnylam Pharmaceuticals, Inc.'s enterprise value stands at 81.4x EBITDA, 17% below its 5-year average of 98.5x. The Healthcare sector median is 13.8x, placing the stock at a 488% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.77 | 14.15 | 13.35 | 28.31 | 24.00 | 30.37 | 56.16 | 92.70 | 121.11 | 67.03 |
| EV / EBITDA | 81.44 | 98.47 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 90.48 | 109.39 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 117.90 | — | 581.74 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Alnylam Pharmaceuticals, Inc. earns an operating margin of 13.5%. Operating margins have expanded from -15.4% to 13.5% over the past 3 years, signaling improving operational efficiency. Return on equity of 73.3% is exceptionally high. ROIC of 19.1% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8% | 81.8% | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% | 88.6% | 97.6% | 85.1% | 100.0% |
| Operating Margin | 13.5% | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | -556.2% | -900.3% |
| Net Profit Margin | 8.4% | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% | -403.2% | -1016.6% | -545.9% | -869.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 73.3% | 73.3% | -414.6% | — | -526.1% | -106.3% | -69.9% | -64.7% | -49.6% | -36.5% | -37.5% |
| ROA | 6.8% | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% |
| ROIC | 19.1% | 19.1% | -12.5% | -74.6% | -110.9% | -58.8% | -55.6% | -66.9% | -59.2% | -37.0% | -32.5% |
| ROCE | 15.3% | 15.3% | -6.0% | -10.0% | -27.4% | -24.6% | -34.1% | -54.7% | -50.2% | -33.5% | -34.6% |
Solvency and debt-coverage ratios — lower is generally safer
Alnylam Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 5.3x, which is highly leveraged (71% above the sector average of 3.1x). Net debt stands at $1.3B ($3.0B total debt minus $1.7B cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.76 | 3.76 | 40.89 | — | — | 1.70 | 0.51 | 0.21 | 0.02 | 0.02 | 0.16 |
| Debt / EBITDA | 5.33 | 5.33 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.66 | 26.49 | — | — | 0.30 | 0.02 | -0.17 | -0.30 | -0.35 | -0.05 |
| Net Debt / EBITDA | 2.35 | 2.35 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 2.82 | — | 11.75 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -1.25 | -2.33 | -5.03 | -4.95 | -9.80 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
Alnylam Pharmaceuticals, Inc.'s current ratio of 2.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.08x to 2.76x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.76 | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 6.69 | 12.23 | 5.10 |
| Quick Ratio | 2.71 | 2.71 | 2.71 | 2.99 | 3.34 | 3.91 | 4.34 | 4.71 | 6.56 | 12.23 | 5.10 |
| Cash Ratio | 1.98 | 1.98 | 2.27 | 2.52 | 2.86 | 3.50 | 3.20 | 4.36 | 6.04 | 11.72 | 4.76 |
| Asset Turnover | — | 0.75 | 0.53 | 0.48 | 0.29 | 0.23 | 0.14 | 0.09 | 0.05 | 0.05 | 0.04 |
| Inventory Turnover | 8.19 | 8.19 | 4.12 | 3.48 | 1.31 | 1.62 | 1.04 | 0.44 | 0.07 | — | — |
| Days Sales Outstanding | — | 76.42 | 65.80 | 65.44 | 83.72 | 85.85 | 446.14 | 71.44 | 91.41 | 138.03 | 180.60 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alnylam Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.7% | 0.6% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.1% | 0.9% | — | 0.2% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $135M | $128M | $125M | $122M | $118M | $115M | $109M | $101M | $91M | $86M |
Compare ALNY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ALNYYou | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 24 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ALNY stacks up against sector leader Ionis Pharmaceuticals, Inc..
Start ComparisonAlnylam Pharmaceuticals, Inc.'s current P/E ratio is 142.9x. The historical average is 170.7x.
Alnylam Pharmaceuticals, Inc.'s current EV/EBITDA is 81.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 98.5x.
Alnylam Pharmaceuticals, Inc.'s return on equity (ROE) is 73.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -75.5%.
Based on historical data, Alnylam Pharmaceuticals, Inc. is trading at a P/E of 142.9x. Compare with industry peers and growth rates for a complete picture.
Alnylam Pharmaceuticals, Inc. has 81.8% gross margin and 13.5% operating margin. Operating margin between 10-20% is typical for established companies.
Alnylam Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 5.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.